FindTrial
Sign In

Usefulness of lifetigrast eyedrops for treating dry eye disease in people suffering from diseases of the immune system

Efficacy of topical Lifetigrast for the treatment of immune mediated dry eye disease at a tertiary care centre - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100545
Enrollment
30
Registered
2026-01-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H041- Other disorders of lacrimal gland

Interventions

Intervention1: Topical lifitegrast 5%: Topical lifitegrast 5% will be prescribed for use in patients with immune-mediated dry eye disease for 3 months Control Intervention1: Nil: NA

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Established history of immune-mediated bilateral dry eye disease, as per DEWS II criteria or DEWS III criteria in patients with Sjogren s syndrome, DED associated with connective tissue diseases, OGVHD

Exclusion criteria

Exclusion criteria: Active infections, keratitis, exposure changes, previous ocular surgeries within 3 months, pregnancy

Design outcomes

Primary

MeasureTime frame
In patients with immune-mediated dry eye disease, assess improvements in eye dryness scores and ocular staining scores following instillation of topical lifitegrast 5% after 12 weeks.Timepoint: Baseline and 12 weeks after treatment—

Secondary

MeasureTime frame
In patients with immune-mediated dry eye disease, assess improvements in conjunctival goblet cells (number and area) following instillation of topical lifitegrast 5% after 12 weeks.Timepoint: Baseline and 12 weeks after treatment—

Countries

India

Contacts

Public ContactGeeta Behera

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)

geeta.anandaraja@gmail.com04132296656

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026